Dr. Iacovelli on the Rationale of the ARIES Trial in Urothelial Cancer

Roberto Iacovelli, MD, PhD, medical oncologist, the Fondazione Policlinico Gemelli IRCCS, Rome, Italy, discusses the rationale of the phase 2 ARIES trial (NCT03891238) in urothelial cancer.

Cisplatin-based chemotherapy remains the most recommended option for most patients with advanced urothelial cancer, Iacovelli says. However, about half of patients are ineligible to receive cisplatin-based chemotherapy, Iacovelli explains. Additionally, a subgroup of patients is ineligible for all forms of chemotherapy, Iacovelli adds.

The ARIES trial focused on the specific group of patients ineligible for cisplatin-based chemotherapy, Iacovelli continues. The goal of this study was to test the activity and safety of avelumab (Bavencio) in this patient population, Iacovelli concludes.